Intrahepatic cholangiocarcinoma: current perspectives

Stefan Buettner  
Jeroen LA van Vugt  
Jan NM IJzermans  
Bas Groot Koerkamp

Department of Surgery, Erasmus MC University Medical Center, Rotterdam, the Netherlands

**Abstract:** Intrahepatic cholangiocarcinoma (ICC) is the second most common malignancy arising from the liver. ICC makes up about 10% of all cholangiocarcinomas. It arises from the peripheral bile ducts within the liver parenchyma, proximal to the secondary biliary radicals. Histologically, the majority of ICCs are adenocarcinomas. Only a minority of patients (15%) present with resectable disease, with a median survival of less than 3 years. Multidisciplinary management of ICC is complicated by large differences in disease course for individual patients both across and within tumor stages. Risk models and nomograms have been developed to more accurately predict survival of individual patients based on clinical parameters. Predictive risk factors are necessary to improve patient selection for systemic treatments. Molecular differences between tumors, such as in the epidermal growth factor receptor status, are promising, but their clinical applicability should be validated. For patients with locally advanced disease, several treatment strategies are being evaluated. Both hepatic arterial infusion chemotherapy with floxuridine and yttrium-90 embolization aim to downstage locally advanced ICC. Selected patients have resectable disease after downstaging, and other patients might benefit because of postponing widespread dissemination and biliary obstruction.

**Keywords:** intrahepatic cholangiocarcinoma, diagnosis, treatment, developments

**Incidence and risk factors**

The incidence of intrahepatic cholangiocarcinoma (ICC) in the Western world is approximately one to two per 100,000. ICC is the second most common malignancy arising from the liver, accounting for 3% of all cases of gastrointestinal cancer. ICC makes up about 10% of all cholangiocarcinomas. It arises in peripheral bile ducts within the liver parenchyma, proximal to the secondary biliary radicals (Figure 1). It should be distinguished from perihilar cholangiocarcinoma arising near the biliary confluence and distal cholangiocarcinoma arising near the head of the pancreas. Only a minority (15%) of ICC patients present with resectable disease at the time of diagnosis. Complete surgical resection remains the only option for cure with an estimated median survival ranging from 27 to 36 months (Figure 2).

Over three-quarters of patients are older than 65 years at initial diagnosis, and ICC is slightly more common in men. ICC is more common in East Asia; in the People’s Republic of China, an incidence of 10 per 100,000 persons has been reported, while in Thailand, the incidence is 71 per 100,000, higher than for hepatocellular carcinoma (HCC).

In general, ICC has similar risk factors to HCC. A correlation with diseases causing biliary inflammation and fibrosis, such as primary sclerosing cholangitis and primary biliary cirrhosis, has been noted. Other risk factors for ICC are congenital...
malformations of the bile duct (ie, choledochal cysts), hepatolithiasis, hepatitis B and C virus, alcoholic liver cirrhosis, and smoking. In East Asia, hepatic parasite infections, in particular *Opisthorchis viverrini* and *Clonorchis sinensis*, are significant risk factors. The reason for the vast difference in incidence between the east and west is not fully understood, as it cannot be attributed completely to the spread of the infectious risk factors.

**Histology**

ICC mostly develops as a well-differentiated adenocarcinoma. Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene. A critical signaling protein downstream of KRAS and p53 mutations is interleukin (IL) 6, which is a serum biomarker for ICC. Further downstream, ROS1 fusion proteins, regulated by KRAS/IL-6 pathways, have been associated with an aggressive phenotype and metastatic disease at diagnosis.

Based on their histological appearance, ICCs can be divided into three histological growth types: the mass-forming, intraductal infiltrating, and periductal pattern. The most common of these growth patterns is the mass-forming pattern, of which the clinical symptoms may be similar to HCC as both involve the formation of a mass in the liver. On imaging (ie, computed tomography [CT] and magnetic resonance imaging [MRI]), these tumors are clearly visible and well delineated. Mass-forming ICC typically has a diameter of 5–10 cm at the time of diagnosis. Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types. On imaging, it is a 1–2 cm mass within the bile duct with proximal ductal dilatation. The mass is usually confined to the bile duct wall. Periductal infiltrating cholangiocarcinoma is characterized by growth along the bile duct without mass formation, which radiologically presents as a small lesion or diffuse bile duct thickening. This type of tumor is a rare form of ICC and is commonly seen in combination with mass-forming ICC. The different histological appearances of cholangiocarcinoma necessitate different surgical strategies, since tumors growing along the bile duct (intraductal and periductal ICC) often require extrahepatic bile duct resection in addition to hepatic resection.

ICC and HCC may occur simultaneously in the same patient or even in the same lesion. Combined HCC and ICC tumors mostly follow the more aggressive behavior of ICC. Because of similar allelic losses in both HCC-like and ICC-like cells, these tumors are thought to have a monoclonal origin with bidirectional phenotype differentiation. In concordance with this hypothesis, a Korean group recently suggested that the acquisition of ICC characteristics is a leading cause of atypically aggressive HCC behavior. Further research in the fields of imaging and molecular analysis is required to improve early diagnosis.

**Staging**

The most commonly used classification system to qualify advancement and resectability of ICC is the American Joint Committee on Cancer (AJCC) TNM staging system, currently in its seventh edition, consisting of four stages...
Intrahepatic cholangiocarcinoma (Table 1).

Prior to this edition, there was no separate staging system for ICC, and these tumors were classified with HCC. The T-stage is determined by the number of liver tumors, the presence of vascular invasion, and direct extrahepatic invasion. The T4 stage is reserved for tumors with a periductal growth pattern. N1 indicates the presence of regional lymph node metastases, and M1 indicates distant metastases.

Recent research suggests the AJCC staging system performs poorly in differentiating between various prognoses, with vast inter-patient survival differences within TNM stages. Additional independent prognostic factors have been identified to improve staging, including elevated serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA), lympho(neuro)vascular invasion, and serum alkaline phosphatase (ALP).

A genomic biomarker profile can also help in differentiating patients with ICC. A genomic study of 149 patients with ICC identified two molecular subgroups, an inflammation and a proliferation group, with distinct clinical outcomes. The inflammation subclass (40%) showed increased activation of inflammation pathways, overexpression of IL-6, IL-10, and IL-17, and constitutive activation of immune system transcription factor STAT3. The proliferation subclass (60%) showed increased activation of oncogenic pathways RAS/MAPK and MET, specific DNA mutations, and risk factors for poor clinical outcome.

In a recent meta-analysis, we identified several immunohistochemistry biomarkers for patients with ICC. An example of a diagnostic and prognostic biomarker is fascin, an actin cross-linked protein found in the cell membrane of the biliary duct cells. The epidermal growth factor receptor also plays an important role in prognostics and is a potential treatment target. Mucin 1, cell surface associated and Mucin 4, cell surface associated are two membrane proteins that have been shown to be associated with patient prognosis. Lastly, p27, cyclin-dependent kinase inhibitor 1B, is a protein involved in the cell cycle, which also has predictive capabilities in relation to postoperative survival.

A composite biomarker profile could improve prognosis and guide treatment selection.

### Diagnosis and preoperative workup

The initial diagnosis of ICC is mostly made when the tumor is not eligible for resection because of locally advanced or metastatic disease. Typically, a very large mass has developed in the periphery of the liver with few clinical symptoms. Most patients present with nonspecific symptoms, such as pain in the right upper abdominal quadrant,
weight loss, and high serum ALP levels. Some patients present with painless jaundice, when the tumor grows towards the biliary confluence. Small ICCs are found in screening programs for early detection of HCC. Transabdominal ultrasound is often the first imaging modality that detects a liver mass with or without dilatation of the biliary tract. The number of lesions and vascular involvement are determined using a dual-phase multi-detector CT. Typical appearance of ICC on CT is a hypodense mass with irregular margins on unenhanced scans, peripheral rim enhancement in the arterial-contrast-enhancement phase, and progressive contrast uptake in the (portal-)venous and delayed contrast-enhancement phase. Small ICCs can be difficult to distinguish from HCC. Biliary drainage (if needed) should be performed after imaging because the presence of stents and drains hampers accurate assessment of the extent of the tumor. Both magnetic resonance cholangiopancreatography (MRCP) and positron emission tomography (PET) have a good accuracy for diagnosis and assessment of the extent of the tumor. MRCP has a diagnostic accuracy of up to 93% and is recommended for visualization of the tumor extension in the ductal system and vascular structures. Clinical utility of PET for diagnosing ICC in the liver when CT or MRI has been performed is limited. However, preoperative PET scanning may be considered to help rule out occult metastatic disease, as PET changes surgical decision making in up to 30% of patients. Despite these imaging modalities, as many as a third of patients with resectable disease on imaging have occult metastatic or locally advanced disease during diagnostic laparoscopy. Therefore, better imaging is needed to avoid surgery in these patients.

**Biliary drainage and portal vein embolization**

ICC may cause biliary obstruction when the tumor grows towards the liver hilum. Biliary drainage may be required in the preoperative setting with resectable disease and in the palliative setting. Biliary drainage aims to improve liver function and increase appetite. Moreover, preoperative biliary drainage may improve liver regeneration and decrease the risk of postoperative liver failure. The main drawback of biliary drainage is colonization of the bile duct that often results in cholangitis. Patients with a future liver remnant of at least 50% should probably undergo a resection without preoperative biliary drainage. Drainage can be performed endoscopically or percutaneously. Biliary drainage can reduce symptoms and improve quality of life in the palliative setting.

A resection of more than 75% of the total liver volume in a healthy liver and more than 65% of the total liver volume in a compromised liver (eg, due to cirrhosis or fibrosis) is an indication of portal vein embolization (PVE). PVE results in hypertrophy of the future liver remnant by preoperatively embolizing the liver that will be resected. In a total of 1,791 patients with different hepatic tumors, PVE had a technical success of 96.1%.

**Surgical management**

**Resection**

Surgical treatment is the only potentially curative treatment in patients with ICC. ICC is an aggressive cancer, when compared to other primary hepatic neoplasms. A large study (n=584) demonstrated that even after curative-intent resection, the probability of cure is only about 10%. Because of the large size as well as intraductal and periductal spread, major hepatectomies are required to obtain negative resection margins. With regard to prognosis, resection is only useful when a complete resection (R0) with negative resection margins is anticipated. Moreover, the liver remnant should be adequate in size and function, with or without prior PVE. Extrhepatic disease, including lymph node metastases beyond the regional basin (N2), is a contraindication for curative-intent surgery. Multifocal ICC is considered unresectable by some experts. Nevertheless, other experts report favorable long-term outcomes in selected patients with typically two to three lesions, with a 5-year overall survival (OS) of 20%. A 2015 cure model confirms the possibility of cure, albeit at a chance of only 4%. Recent studies have reported favorable outcomes of portal vein reconstructions. However, tumor invasion of the main hepatic artery and bilateral hepatic artery involvement remain contraindications for resection in most Western centers. Hepatic artery reconstruction is associated with a high risk of postoperative mortality as well as poor oncologic outcomes. A complete resection of ICC involves an (extended) hemihepatectomy in most (75%) of patients. Many patients (25%) also require a bile duct resection and reconstruction. Morbidity rates are often more than one in five, and mortality rates vary from 1% to 6%. Intraoperative and postoperative strategies, such as low central venous pressure, restricted fluid resuscitation, and enhanced recovery pathways, have improved recovery and decreased the risk of complications. A recent article reviewed perioperative management of patients undergoing hepatic resection. The authors noted that surgeons left an operative drain in almost half of patients undergoing liver resection, even though most data suggest that routine operative drainage after liver

---

**References**

1. Buettner et al. (2017) OncoTargets and Therapy 10:1134-1153. DOI: 10.2147/OTT.S148122
2. Remarks on the manuscript by: OncoTargets and Therapy 2017:10

---

**Submit your manuscript** | www.dovepress.com

Dovepress

OncoTargets and Therapy 2017:10
resection (without a biliary anastomosis) is unnecessary and should generally be avoided.94–96

Whereas HCC is commonly treated with orthotopic liver transplantation (OLT), ICC as an indication for OLT is still controversial.97 Historical evidence suggests poor outcomes for ICC in single-center studies.98–104 Outcomes of OLT for combined HCC and ICC were also predominantly unfavorable.98,105 Five-year survival estimates in these studies ranged from 10% to 18%, which is clearly inferior to the benchmark of OLT of about 70%.97 More recent studies indicate that strictly selected patients might benefit from OLT, particularly patients with ICC smaller than 2 cm.106

Systemic chemotherapy
Preoperative chemotherapy
Preoperative chemotherapy (pCT) can be administered for multiple purposes, although it is not routinely prescribed due to a lack of evidence.107 Neoadjuvant therapy is employed to address occult metastatic disease or facilitate resection. We recently evaluated the role of pCT in a cohort of 1,057 patients, of whom 62 patients received chemotherapy. We found that patients receiving pCT had similar survival following curative-intent resection, regardless of more advanced disease.107 No regimen is currently proven to have effect during the preoperative period. In light of the outcomes of the ABC-02 trial, discussed later, a combination of gemcitabine and cisplatin was offered most often.108

Adjuvant chemotherapy
Adjuvant chemotherapy is aimed at decreasing the chance of tumor recurrence.109 Chemotherapy consists of mainly nucleoside analogs, most commonly gemcitabine, sometimes in combination with cisplatin.109 Systemic therapy is known to have a large impact on patient’s quality of life, and form a large financial burden. The efficacy of chemotherapy regimens in ICC is usually poor, with only a small subgroup benefitting significantly in both quality of life and length of survival.16,109 While a significant portion of the US patients receive chemotherapy, no randomized trials have been completed.42 A multicenter phase III trial is currently accruing patients to determine the effectiveness of adjuvant gemcitabine and cisplatin in patients with biliary cancer (Table 2).

Palliative chemotherapy
A phase III trial, the ABC-02 trial, randomized 410 patients with biliary cancer (ie, cholangiocarcinoma and gallbladder cancer) and found an improvement in OS of nearly 4 months with gemcitabine plus cisplatin compared to gemcitabine alone.108 A combined analysis of the ABC-02 trial and the
Table 2 (Continued)

| Title                                                                 | Collaborators                                                                 | Country/region | Interventions                                                                 | No of patients | Outcome measures                                                                 | Recruitment start | Completion date | NCT number   |
|----------------------------------------------------------------------|-------------------------------------------------------------------------------|----------------|-------------------------------------------------------------------------------|----------------|---------------------------------------------------------------------------------|------------------|----------------|--------------|
| RFA RCT for Pancreatic or Bile Duct Cancer                           | Weill Medical College of Cornell University                                   | US             | Radiofrequency ablation using EndoHPB probe vs stenting only                  | 44             | Clinical success, mutational profile of DNA                                       | Jun-14           | Jun-17         | NCT02166190 |
| Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma | Tata Memorial Hospital                                                        | India          | High-dose radiation and systemic chemotherapy Gemcitabine and cisplatin vs mFOLFIRINOX | 155            | Overall survival, progression-free survival, toxicity, quality of life, surgical resectability rates | May-15           | Jun-22         | NCT02773485 |
| Safety and Efficacy of Modified Folfirinox Versus Gemcitabine in Bile Duct Tumours | Centre Hospitalier Universitaire de Saint Etienne| France | Gemcitabine and cisplatin vs mFOLFIRINOX                                     | 316            | Progression-free survival, overall survival, response rate, toxicity               | Nov-15           | Jun-18         | NCT02591030 |
| Study of SPARC1507 (Sun Pharma Advanced Research Company Limited Drug) | Sun Pharma Advanced Research Company Limited                                  | India          | SPARC1507                                                                     | 198            | Progression-free survival, overall survival, response rate                        | Apr-16           | Nov-19         | NCT02597465 |
| Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy | Centre Oscar Lamberi| France | Early palliative care                                                         | 558            | Overall survival, quality of life, reduction in depression score, time until definitive deterioration, advanced directives, number of patients treated with chemotherapy | Aug-16           | Aug-20         | NCT02853474 |
| Adjuvant setting                                                      |                                                                                |                |                                                                               |                |                                                                                  |                  |                |              |
| Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Biliary Tract Cancer, ACTICCA | Universitätsklinikum Hamburg-Eppendorf| Germany          | Gemcitabine and cisplatin                                                     | 440            | Disease-free survival, overall survival, toxicity, quality of life, function biliodigestive anastomosis, infections | Apr-14           | Apr-22         | NCT02170090 |
| Oxaliplatin + Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma | Shanghai Zhongshan Hospital| China             | Gemcitabine and cisplatin                                                     | 286            | Recurrence-free survival, overall survival                                        | Jul-15           | Dec-18         | NCT02548195 |

Abbreviations: FOLFOX, chemotherapy regimen consisting of folinic acid (leucovorin), 5-fluorouracil (5-FU), and oxaliplatin; FOLFIRINOX, chemotherapy regimen consisting of folinic acid (leucovorin), 5-fluorouracil (5-FU), irinotecan, and oxaliplatin; ICU, intensive care unit; RFA, radiofrequency ablation; RCT, randomized controlled trial.
Regional treatments

Regional treatments rely on the dual blood supply of the liver, where the hepatic artery is mostly responsible for the blood supply of tumors, as illustrated by early arterial enhancement on imaging. Hepatic arterial infusion (HAI) chemotherapy using a subcutaneous pump has been investigated for patients with ICC at Memorial Sloan Kettering Cancer Center (MSKCC). It involves continuous infusion of floxuridine directly into the hepatic artery. Intraarterial delivery allows for a 200-fold higher drug delivery to the tumor with little systemic toxicity because of the 95% first-pass effect of floxuridine in the liver. HAI chemotherapy has been studied extensively in common malignancies, such as colorectal liver metastases.

In a recent study from MSKCC, HAI with floxuridine was combined with systemic chemotherapy in patients with locally advanced (ie, unresectable without extrahepatic disease) ICC (n=104). Outcomes were compared with locally advanced patients receiving systemic chemotherapy alone. Median OS was superior with HAI chemotherapy (30.8 months vs 18.4 months; \(P<0.001\)). Five-year OS was 20% in patients who received HAI chemotherapy compared with 5% in the systemic-only group. In comparison, 5-year OS was 0% in the ABC-02 trial. Moreover, the partial response rate (RECIST criteria) in the HAI chemotherapy group was 59%, with conversion to resectability in eight of 104 patients (13%). Future prospective studies should be conducted in order to confirm these results. Currently, a phase II trial is recruiting patients for HAI chemotherapy in the adjuvant setting (NCT01312857).

Other hepatic artery-based treatments for locally advanced ICC include transarterial chemoembolization (TACE) and radio-embolization with yttrium-90 (Y-90). TACE affects the blood flow to the tumor in addition to locally releasing cytotoxic agents. It causes ischemic tumor necrosis and facilitates intracellular transit of chemotherapeutic agents. In a study of 41 prospectively followed patients, one group described a median OS of 11.7 months from first treatment, after treatment with irinotecan TACE. One patient successfully underwent resection following TACE. Another prospective study reported a median survival of 17.5 months in 24 patients, with three patients being adequately downstaged to undergo resection. Despite the encouraging results, no phase III trial has been performed.

Y-90 radio-embolization therapy also aims to improve life expectancy in patients with unresectable HCC and colorectal liver metastases. The technique is based on administration of beads filled with the radioactive isotope yttrium Y-90 microspheres into the hepatic artery branch responsible for the lobes of the liver beset by tumor. Prior to treatment, embolization of the nontarget vessels and injection of technetium-99m-labeled macro-aggregated albumin is performed, in order to exclude extrahepatic accumulation. Several small studies indicate that Y-90 is tolerated well in patients with a good performance status. In ICC patients, Y-90 was associated with improved survival, when compared with patients undergoing best supportive care only. Estimates ranged from 9 months posttreatment in a cohort of 25 Australian patients, to 22 months in a cohort of 33 German patients. Randomized trials are required to determine the effectiveness of Y-90 therapy.

Prognostic models and nomograms

Several prognostic models have been developed in addition to the AJCC staging. More accurate prediction of individual patient outcome may provide better individual survival estimates, as well as improve identification of high-risk groups who may benefit from adjuvant therapy. While the AJCC staging concerns all ICC patients, other models pertain only to patients who have undergone a complete resection. A Chinese nomogram predicts individual OS after resection of ICC (Figure 3). Prognostic factors in this model included CEA, CA19-9, vascular invasion, presence of lymph node metastases, direct invasion and local metastases, number of tumors, and tumor diameter. A similar model was developed with a multinational dataset without tumor markers. Risk factors for survival after resection were age, number of tumors, tumor diameter, cirrhosis, lymph node metastases, and macrovascular invasion. The Chinese nomogram had superior discrimination at external validation.

Other prognostic models were developed for conditional survival, accounting for the years that a patient had already survived after surgery. Conditional survival was found to be the most important prognostic factor, when predicting future survival time. OS in this study decreased over time to 16% at 8 years, while the 3-year conditional survival at 5 years, that is, the chance of surviving to year 8 after having survived to year 5, was 65%.
Personalized treatments

Personalized treatments for ICC patients could improve the overall outcomes, mainly by withholding treatments from patients who are unlikely to benefit from surgery or chemotherapy. For example, patients with a very poor predicted survival after surgery (e.g., 3-year OS below 5% based on the Chinese nomogram in Figure 3) are unlikely to benefit from surgery. Unfortunately, predictive biomarkers for response to systemic chemotherapy are not available. Future studies should further improve prognostic models and identify predictive biomarkers to determine the response to chemotherapy.11,12

Future perspectives

ICC is a complex disease, with a dismal prognosis. ICC is typically diagnosed with metastatic or locally advanced disease. Surgery may improve both survival and quality of life, but comes with a substantial risk of postoperative morbidity and mortality. The benefit of palliative systemic treatment is real but small. The merits of (neo)adjuvant therapy still need to be explored in phase III trials. Targeted therapies (e.g., targeting IDH 1 or 2 mutations) are promising but require further evaluation.13 HAI, TACE, and radio-embolization are promising locoregional techniques. Appropriate allocation of all locoregional and systemic treatments may further improve with better knowledge of histopathology and biological behavior.

Ideally, low-cost diagnostic biomarkers could reliably detect ICC in patients presenting with vague symptoms of the upper abdomen or screened for liver cancer. Furthermore, predictive biomarkers are required to determine in advance which patients will benefit from chemotherapy.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Shin HR, Oh JK, Masuyer E, et al. Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma – focus on East and South-Eastern Asia. Asian Pac J Cancer Prev. 2010;11(5):1159–1166.
2. Singal AK, Vauthney JN, Grady JJ, Stroehlein JR. Intra-hepatic cholangiocarcinoma – frequency and demographic patterns: thirty-year data from the M.D. Anderson Cancer Center. J Cancer Res Clin Oncol. 2011;137(7):1071–1078.
3. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part III: liver, biliary tract, and pancreas. Gastroenterology. 2009;136(4):1134–1144.
4. DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245(5):755–762.
5. Konstantinidis IT, Groot Koerkamp B, Do RK, et al. Unresectable intrahepatic cholangiocarcinoma: systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer. 2016;122(5):758–765.
6. Esnaola NF, Meyer JE, Karachristos A, Marangi JL, Camp ER, Denlinger CS. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer. 2016;122(9):1349–1369.
7. Nakane Y, Sato Y, Harada K, Sasaki M, Xu J, Ikeda H. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol. 2010;2(12):113–120.

8. O’Dell MR, Huang JL, Whitney-Miller CL, et al. KRAS(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res. 2004;64(20):6694–6700.

9. Olnes MJ, Erlich R. A review and update on cholangiocarcinoma. Oncology. 2004;9(1):43–57.

10. Olness MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MRI with emphasis on hepaticobiliary phase. Liver Int. 2015;35(2):167–179.

11. Overgaard M, Hansen JH, Krarup J, et al. Intrahepatic cholangiocarcinoma: classification of intrahepatic cholangiocarcinoma based on a new concept. J Hepatol. 2010;52(5):962–969.

12. Overgaard M, Hansen JH, Krarup J, et al. Intrahepatic cholangiocarcinoma: classification of intrahepatic cholangiocarcinoma based on a new concept. J Hepatol. 2010;52(5):962–969.

13. Overgaard M, Hansen JH, Krarup J, et al. Intrahepatic cholangiocarcinoma: classification of intrahepatic cholangiocarcinoma based on a new concept. J Hepatol. 2010;52(5):962–969.

14. Overgaard M, Hansen JH, Krarup J, et al. Intrahepatic cholangiocarcinoma: classification of intrahepatic cholangiocarcinoma based on a new concept. J Hepatol. 2010;52(5):962–969.

15. Overgaard M, Hansen JH, Krarup J, et al. Intrahepatic cholangiocarcinoma: classification of intrahepatic cholangiocarcinoma based on a new concept. J Hepatol. 2010;52(5):962–969.

16. Overgaard M, Hansen JH, Krarup J, et al. Intrahepatic cholangiocarcinoma: classification of intrahepatic cholangiocarcinoma based on a new concept. J Hepatol. 2010;52(5):962–969.

17. Overgaard M, Hansen JH, Krarup J, et al. Intrahepatic cholangiocarcinoma: classification of intrahepatic cholangiocarcinoma based on a new concept. J Hepatol. 2010;52(5):962–969.

18. Overgaard M, Hansen JH, Krarup J, et al. Intrahepatic cholangiocarcinoma: classification of intrahepatic cholangiocarcinoma based on a new concept. J Hepatol. 2010;52(5):962–969.

19. Overgaard M, Hansen JH, Krarup J, et al. Intrahepatic cholangiocarcinoma: classification of intrahepatic cholangiocarcinoma based on a new concept. J Hepatol. 2010;52(5):962–969.

20. Overgaard M, Hansen JH, Krarup J, et al. Intrahepatic cholangiocarcinoma: classification of intrahepatic cholangiocarcinoma based on a new concept. J Hepatol. 2010;52(5):962–969.

21. Overgaard M, Hansen JH, Krarup J, et al. Intrahepatic cholangiocarcinoma: classification of intrahepatic cholangiocarcinoma based on a new concept. J Hepatol. 2010;52(5):962–969.
51. Herberberger B, Berger W, Puhalla H, et al. Simultaneous blockade of the epidermal growth factor receptor/mammary target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. *Mol Cancer Ther*. 2009;8(6):1547–1556.

52. Higashi M, Yamada N, Yokoyama S, et al. Pathobiological implications of MUC16/C125 expression in intrahepatic cholangiocarcinoma—mass forming type. *Pathobiology*. 2012;79(2):101–106.

53. Park SY, Roh SJ, Kim YN, et al. Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact. *Onco Rep*. 2009;22(3):649–657.

54. Yeh CN, Pang ST, Wu RC, Chen TW, Jan YY, Chen MF. Prognostic value of MUC4 for mass-forming intrahepatic cholangiocarcinoma after hepatectomy. *Onco Rep*. 2009;21(1):49–56.

55. Hashimoto N, Yachida S, Okano K, et al. Immunohistochemically detected expression of p27(Kip1) and Skp2 predicts survival in patients with intrahepatic cholangiocarcinomas. *Ann Surg Oncol*. 2009;16(2):395–403.

56. Jarnagin WR, Klimstra DS, Hezel M, et al. Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcomes. *J Clin Oncol*. 2006;24(7):1152–1160.

57. Fiorentino M, Altmani A, D’Errico A, et al. Low p27 expression is an independent predictor of survival for patients with either hilar or peripheral intrahepatic cholangiocarcinoma. *Clin Cancer Res*. 2001;7(12):3994–3999.

58. Razumilava N, Gores GJ. Cholangiocarcinoma. *Lancet*. 2014;383(9935):2168–2179.

59. Razumilava N, Gores GJ. Cholangiocarcinoma. *Clin Cancer Res*. 2006;12(24):1482–1486.

60. Razumilava N, Gores GJ. Cholangiocarcinoma. *Cancer*. 2013;119(16):2952–2961.

61. Razumilava N, Gores GJ. Cholangiocarcinoma. *World J Gastroenterol*. 2015;21(4):1113–1120.

62. Razumilava N, Gores GJ. Cholangiocarcinoma. *Gastroenterology*. 2014;146(2):330–346.

63. Razumilava N, Gores GJ. Cholangiocarcinoma. *Clin Cancer Res*. 2014;20(20):5263–5271.

64. Razumilava N, Gores GJ. Cholangiocarcinoma. *Intervent Radiol*. 2013;36(12):159–168.

65. Razumilava N, Gores GJ. Cholangiocarcinoma. *World J Gastroenterol*. 2013;19(28):4555–4562.

66. Razumilava N, Gores GJ. Cholangiocarcinoma. *Gastroenterology*. 2013;144(5):1338–1352.

67. Razumilava N, Gores GJ. Cholangiocarcinoma. *Am J Gastroenterol*. 2013;108(5):771–782.

68. Razumilava N, Gores GJ. Cholangiocarcinoma. *World J Gastroenterol*. 2013;19(35):5799–5805.

69. Razumilava N, Gores GJ. Cholangiocarcinoma. *Intervent Radiol*. 2013;36(1):25–34.

70. Razumilava N, Gores GJ. Cholangiocarcinoma. *World J Gastroenterol*. 2013;19(30):4656–4666.

71. Razumilava N, Gores GJ. Cholangiocarcinoma. *Gastroenterology*. 2013;144(3):532–541.

72. Razumilava N, Gores GJ. Cholangiocarcinoma. *World J Gastroenterol*. 2013;19(4):521–532.

73. Razumilava N, Gores GJ. Cholangiocarcinoma. *World J Gastroenterol*. 2013;19(20):3744–3752.

74. Razumilava N, Gores GJ. Cholangiocarcinoma. *World J Gastroenterol*. 2013;19(36):5803–5811.

75. Razumilava N, Gores GJ. Cholangiocarcinoma. *World J Gastroenterol*. 2013;19(37):6994–7003.

76. Razumilava N, Gores GJ. Cholangiocarcinoma. *World J Gastroenterol*. 2013;19(38):7625–7632.

77. Razumilava N, Gores GJ. Cholangiocarcinoma. *World J Gastroenterol*. 2013;19(39):8634–8641.

78. Razumilava N, Gores GJ. Cholangiocarcinoma. *World J Gastroenterol*. 2013;19(40):9033–9040.

79. Razumilava N, Gores GJ. Cholangiocarcinoma. *World J Gastroenterol*. 2013;19(41):10011–10019.

80. Razumilava N, Gores GJ. Cholangiocarcinoma. *World J Gastroenterol*. 2013;19(42):10750–10759.

81. Razumilava N, Gores GJ. Cholangiocarcinoma. *World J Gastroenterol*. 2013;19(43):11326–11333.

82. Razumilava N, Gores GJ. Cholangiocarcinoma. *World J Gastroenterol*. 2013;19(44):11829–11836.

83. Razumilava N, Gores GJ. Cholangiocarcinoma. *World J Gastroenterol*. 2013;19(45):12429–12436.

84. Razumilava N, Gores GJ. Cholangiocarcinoma. *World J Gastroenterol*. 2013;19(46):13074–13081.

85. Razumilava N, Gores GJ. Cholangiocarcinoma. *World J Gastroenterol*. 2013;19(47):13609–13616.

86. Razumilava N, Gores GJ. Cholangiocarcinoma. *World J Gastroenterol*. 2013;19(48):14168–14177.

87. Razumilava N, Gores GJ. Cholangiocarcinoma. *World J Gastroenterol*. 2013;19(49):14763–14772.

88. Razumilava N, Gores GJ. Cholangiocarcinoma. *World J Gastroenterol*. 2013;19(50):15365–15372.

89. Razumilava N, Gores GJ. Cholangiocarcinoma. *World J Gastroenterol*. 2013;19(51):15995–16002.

90. Razumilava N, Gores GJ. Cholangiocarcinoma. *World J Gastroenterol*. 2013;19(52):16396–16404.

91. Razumilava N, Gores GJ. Cholangiocarcinoma. *World J Gastroenterol*. 2013;19(53):16844–16850.

92. Razumilava N, Gores GJ. Cholangiocarcinoma. *World J Gastroenterol*. 2013;19(54):17108–17115.
92. Gurusamy KS, Li J, Sharma D, Davidson BR. Cardiopulmonary interventions to decrease blood loss and blood transfusion requirements for liver resection. Cochrane Database Syst Rev. 2009;(4):CD007338.

93. Spolverato G, Ejaz A, Kim Y, et al. Patterns of care among patients undergoing hepatic resection: a query of the National Surgical Quality Improvement Program-Targeted hepatopancreatic database. JSurg Res. 2015;196(2):221–228.

94. Fong Y, Brennan MF, Brown K, Heffernan N, Blumgart LH. Drainage is unnecessary after elective liver resection. Am J Surg. 1996;171(1):158–162.

95. Butte JM, Grendar J, Bathe O, et al. The role of peri-hepatic drain placement in liver surgery: a prospective analysis. HPB (Oxford). 2014;16(10):936–942.

96. Brooke-Smith M, Figueras J, Ullah S, et al. Prospective evaluation of the International Study Group for Liver Surgery definition of bile leak after a liver resection and the role of routine operative drainage: an international multicentre study. HPB (Oxford). 2015;17(1):46–50.

97. Sapisochin G, Fernández de Sevilla E, Echeverri J, Charco R. Liver transplantation for cholangiocarcinoma: current status and new insights. World J Hepatol. 2015;7(22):2396–2403.

98. DeOliveira ML. Liver transplantation for cholangiocarcinoma: current best practice. Curr Opin Organ Transplant. 2014;19(3):245–252.

99. Robles R, Figueras J, Turrion VS, et al. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Am Surg. 2004;69(2):265–271.

100. Casavilla FA, Marsh JI, Iwatsuki S, et al. Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg. 1997;185(5):429–436.

101. Jan YY, Yeh CN, Yeh TS, Chen TC. Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: two decades of experience at Chang Gung Memorial Hospital. World J Gastroenterol. 2005;11(12):1779–1784.

102. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation. 2000;69(8):1633–1637.

103. Ghali P, Marotta PJ, Yoshida EM, et al. Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience. Liver Transpl. 2005;11(11):1412–1416.

104. Weimann A, Varnholt H, Schlitt HJ, et al. Retrospective analysis of prognostic factors after liver resection and transplantation for cholangiocellular carcinoma. Br J Surg. 2000;87(9):1182–1187.

105. Groeschl RT, Pappas SG, Christians KK, et al. Are we justified in excluding combined hepatocellular-cholangiocarcinoma from transplantation? J Clin Oncol. 2012;30(Suppl 4):256.

106. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145(6):1215–1229.

107. Buettner S, Groot Koerkamp B, Ejaz A, et al. The effect of preoperative chemotherapy treatment in surgically treated intrahepatic cholangiocarcinoma patients – a multi-institutional analysis. J Surg Oncol. In press 2016.

108. Valle J, Wasan H, Palmer DH, et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281.

109. Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934–1940.

110. Valle JW, Furuse J, Jitlal M, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014;25(2):391–398.

111. Goenka MK, Goenka U. Palliation: hilar cholangiocarcinoma. World J Hepatol. 2014;6(8):559–569.

112. Taylor MC, McLeod RS, Langer B. Biliary stenting versus bypass surgery for the palliation of malignant distal bile duct obstruction: a meta-analysis. Liver Transpl. 2000;6(3):302–308.

113. Smith AC, Dowsett JF, Russell RC, Hatfield AR, Cotton PB. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bile duct obstruction. Lancet. 1994;344(8938):1655–1660.

114. Andersen JR, Sørensen SM, Kruse A, Rokkjær M, Matzen P. Randomised trial of endoscopic endoprostheses versus operative bypass in malignant obstructive jaundice. Gut. 1989;30(8):1132–1135.

115. Seidensticker R, Ricke J, Seidensticker M. Integration of chemotherapy and radioembolization into multimodal treatment of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015;29(2):319–322.

116. Breida C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30(5):969–977.

117. Llovet JM, Real MJ, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–1739.

118. McAuliffe JC, Qadan M, D’Angelica MI. Hepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancer. J Gastrointest Oncol. 2015;6(6):699–708.

119. Kuhlmann JB, Euringer W, Spangenberg HC, et al. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol. 2012;24(4):437–443.

120. Schiffman SC, Metzger T, Dubel G, et al. Precision hepatic artery yttrium-90 radioembolization therapy in the treatment of unresectable inoperable cholangiocellular carcinoma: optimal tolerance and prolonged overall survival. Ann Surg Oncol. 2011;18(2):431–438.

121. Seidensticker R, Denecke T, Kraus P, et al. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol. 2012;35(5):1066–1073.

122. Sangro B, Carpanese L, Cianni R, et al; European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY). Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54(3):688–687.

123. Camacho JC, Kokabi N, Xing M, Prajapati HH, El-Rayes B, Kim HS. Modified response evaluation criteria in solid tumors and European Association for the Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable inoperable cholangiocarcinoma following yttrium-90 radioembolization. J Vasc Interv Radiol. 2014;25(2):256–265.

124. Mouli S, Memon K, Baker T, et al; Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol. 2013;24(8):1227–1234.

125. Rafl S, Pidurum SM, El-Rayes B, et al. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol. 2013;36(2):440–448.

126. Hoffmann RT, Paprottka PM, Schön A, et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable inoperable cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol. 2012;35(1):105–116.

127. Saxena A, Bester L, Chua TC, Chu FC, Morris DL. Yttrium-90 radiotherapy for unresectable inoperable hepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol. 2010;17(2):484–491.

128. Ibrahim SM, Mulcahy MF, Lewandowski RJ, et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer. 2008;113(8):2119–2128.

129. Hyder O, Marques H, Pulitano C, et al. A nomogram to predict long-term survival after resection for inoperable cholangiocarcinoma: an Eastern and Western experience. JAMA Surg. 2014;149(5):432–438.

130. Kim Y, Ejaz A, Spolverato G, et al. Conditional survival after surgical resection of gastric cancer: a multi-institutional analysis of the US Gastric Cancer Collaborative. Ann Surg Oncol. 2015;22(2):557–564.
131. Nathan H, de Jong MC, Pulitano C, et al. Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients. *J Am Coll Surg*. 2010;210(5):755–764, 764–766.

132. Groot Koerkamp B, Fong Y. Outcomes in biliary malignancy. *J Surg Oncol*. 2014;110(5):585–591.

133. Merla A, Liu KG, Rajdev L. Targeted therapy in biliary tract cancers. *Curr Treat Options Oncol*. 2015;16(10):48.

134. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. *Nat Rev Gastroenterol Hepatol*. 2011;8(9):512–522.